Cellectar Biosciences, Inc. Series A Warrants
CLRBZ
CLRBZ was delisted on the 16th of April, 2021.
2 hedge funds and large institutions have $233K invested in Cellectar Biosciences, Inc. Series A Warrants in 2017 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.
34% more capital invested
Capital invested by funds: $174K → $233K (+$59K)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
50% less funds holding
Funds holding: 4 → 2 (-2)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$3.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ICM
Ionic Capital Management
New York
|
-$61K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$9.61K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $228K | -$9.61K | -15,000 | -6% |
|
|
2
UBS Group
Zurich,
Switzerland
| $5K | +$3.7K | +5,780 | +3,211% |
|
|
ICM
3
Ionic Capital Management
New York
| – | -$61K | -145,035 | Closed |
|
CLRBZ Hedge Fund Activity: Q1 2017 in Review
2 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Cellectar Biosciences, Inc. Series A Warrants (CLRBZ) for Q1 2017, worth a combined $233K — up 34% from $174K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of CLRBZ and 0 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 1 added.
The largest buyer was UBS Group, adding an estimated $3.7K. The largest seller was Ionic Capital Management, exiting entirely with an estimated $61K sold.
- 2 institutional investors held Cellectar Biosciences, Inc. Series A Warrants (CLRBZ) as of Q1 2017, down from 4 in Q4 2016.
- Funds reported $233K of Cellectar Biosciences, Inc. Series A Warrants stock for Q1 2017, up 34% quarter-over-quarter.
- 0 funds opened new Cellectar Biosciences, Inc. Series A Warrants positions in Q1 2017 and 1 closed out, a net change of -1 holder.
- The largest Cellectar Biosciences, Inc. Series A Warrants buyer in Q1 2017 was UBS Group, an estimated $3.7K added.
- The largest Cellectar Biosciences, Inc. Series A Warrants seller in Q1 2017 was Ionic Capital Management, an estimated $61K sold.
Based on aggregated 13F filings for Q1 2017.